pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,076 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1167Endpoints883BioPharma Dive340BioSpace303Fierce Biotech281onclive165raps104globenewswire health73
therapy area
allOncology7491Rare Disease1856Cardiology1708Immunology1472Hematology1313Vaccines1191Pulmonology
  • Garner Health secures $100 million funding, valuation climbs to $2.7 billion
    Garner Health announced a $100 million financing round that pushes its post‑money valuation to $2.7 billion. The capital raise was completed last month and was led by a group of venture investors.…
    Endpoints · 3mo agoDealPositive↗ source
  • Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioTools
    Treeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…
    BioPharma Dive · 3mo agoDealPositive↗ source
← prev
page 60 of 84
next →
fda recalls67
fda medwatch60
fda press38
1127
Psychiatry & CNS864
Ophthalmology494
Pain473
Endocrinology & Metabolism468
Infectious Disease444
  • Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s program
    On June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion bas…
    Endpoints · 3mo agoDealNeutral↗ source
  • Gilead reports positive Phase 3 HIV results while Merck's Trodelvy fails in lung cancer trial
    Gilead Sciences announced that its Phase 3 HIV trial met its primary efficacy endpoint, delivering a positive readout for the experimental therapy. In a separate study, Merck reported that its Pha…
    Endpoints · 3mo agoNeutral↗ source
  • WuXi AppTec re-added to Pentagon list of firms linked to Chinese military
    WuXi AppTec has been placed again on the Pentagon's updated list of companies that have ties to the Chinese military, according to a June 9, 2026 report. The inclusion marks renewed scrutiny of th…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Biopharma workers earned $116,648 on average in 2025, about 30% above S&P 500 peers
    The Endpoints News pay analysis found that the average biopharma employee earned $116,648 in 2025. This figure reflects compensation across the sector for that year. Compared with the broader mark…
    Endpoints · 3mo agoPositive↗ source
  • Eli Lilly's 340B claims data deadline passes, sparking potential new dispute
    Eli Lilly set a deadline for hospitals to submit 340B drug‑pricing program claims data under its new policy. The deadline has now passed, and the company has not indicated what actions it will tak…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
    BioPharma Dive · 3mo agoRegulatoryNeutral↗ source
  • Biopharma CEOs see soaring compensation, new analysis to be discussed live
    Endpoints News released the first installment of its annual biopharma compensation project, breaking down the pay of the industry’s highest-earning CEOs. The company will host a Post-Hoc Live web…
    Endpoints · 3mo agoNeutral↗ source
  • K Health expands AI chatbot from symptom checker to hospital use
    K Health, a startup founded in 2016 as a symptom checking tool, is now deploying its AI chatbot within hospital environments. The shift follows a broader surge in AI driven virtual doctors that pa…
    Endpoints · 3mo agoPositive↗ source
  • Endpoints launches nominations for its 2026 Women in Biopharma project
    Endpoints announced that nominations are now open for its eighth annual Women in Biopharma initiative, which highlights contributions of women in the industry. The program, scheduled for 2026, see…
    Endpoints · 3mo agoPositive↗ source
  • Roche commits $700 million to co-develop Nurix's BTK-degrading drug bexobrutideg
    Roche announced a partnership with Nurix Therapeutics to co-develop a protein-degrading therapy called bexobrutideg, which targets the BTK enzyme. Under the agreement, Roche will pay $700 million…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Lilly’s retatrutide data at ADA 2026 underscores its lead in obesity drug market
    The American Diabetes Association’s 2026 meeting highlighted a wave of new weight‑loss drug data as companies vie for a slice of a market dominated by Eli Lilly and Novo Nordisk. Lilly presented r…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Tango to launch Phase 3 trial in pancreatic cancer after promising combo results
    Tango announced plans to begin a Phase 3 trial testing a combination therapy for pancreatic cancer. The decision follows data presented at the American Society of Clinical Oncology meeting, where…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Roche to pay $700M upfront to Nurix for BTK degrader collaboration, deal up to $2.3B
    Roche announced a collaboration with Nurix Therapeutics to develop a BTK degrader for B cell malignancies. Roche will provide $700 million upfront, and the agreement could be worth up to $2.3 bill…
    Endpoints · 3mo agoDealPositive↗ source
  • AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trial
    AstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment. The trial showed participants lost an average of 10.5% of body weight after six months of therapy. The re…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Incyte to acquire Vega Therapeutics for up to $2 billion, securing late-stage von Willebrand disease drug
    Incyte announced it will purchase Vega Therapeutics, a unit of Star Therapeutics, for $1.25 billion in cash with the possibility of receiving up to $750 million more if future sales targets are met…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • J&J to acquire Firefly Bio for $1 billion, adding degrader-antibody conjugate technology
    J&J announced it will acquire biotech startup Firefly Bio in an all‑cash transaction valued at $1 billion. The deal gives J&J access to Firefly’s degrader‑antibody conjugate platform, which blends…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Treeline Biosciences to go public via reverse merger with Standard BioTools, securing runway to 2029
    Treeline Biosciences announced that it will become a publicly traded company through a reverse merger with Standard BioTools. The transaction is expected to list the combined entity on a U.S. excha…
    Endpoints · 3mo agoDealPositive↗ source
  • J&J to acquire Firefly Bio for $1 billion, boosting its KRAS-focused antibody-degrader program
    Johnson & Johnson announced it will purchase Firefly Bio, a preclinical biotech, for $1 billion in cash. Firefly Bio is developing degrader antibody conjugates that aim to target KRAS-driven cance…
    Endpoints · 3mo agoDealPositive↗ source
  • Incyte agrees to acquire Vega Therapeutics for $1.25 billion upfront
    Incyte announced it will purchase Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction that includes an upfront payment of $1.25 billion. The acquisition gives Incyte control of…
    Endpoints · 3mo agoDealNeutral↗ source
  • City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt disease
    City Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategy
    Incyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi. Meury, who has previ…
    Endpoints · 3mo agoDealPositive↗ source
  • City Therapeutics raises $99.5 million to advance three RNAi drug candidates
    City Therapeutics, a next‑generation RNA interference startup founded by former Alnylam executives, announced it has secured $99.5 million in financing. The capital will be used to move its first…
    Endpoints · 3mo agoDealPositive↗ source
  • GoHealth files for Chapter 11 bankruptcy as Medicare Advantage insurers retreat
    GoHealth, a health‑insurance marketplace that serves seniors, voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court. The filing follows a period of volatility in the Medicare Ad…
    Endpoints · 3mo agoNegative↗ source